Novo Nordisk
Pays vs peer median
×0.70
-30% premium
Sample
18
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| metabolic | ×0.70 | 12 |
| cardiovascular | ×1.20 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×0.72 | 5 |
| phase 1 | ×0.70 | 4 |
| preclinical | ×0.85 | 4 |
| discovery | ×0.70 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | — | Vivtex Therapeutics | metabolic | unknown | — | $2.1B |
| 2026 | once-monthly GLP-1 drug | Ascendis | metabolic disorders | preclinical | — | $285M |
| 2026 | — | Vivtex | obesity/weight loss | discovery | — | $2.1B |
| 2025 | Efruxifermin (EFX) acquisition | Akero Therapeutics | MASH with moderate-advanced fibrosis | phase_3 | $4.7B | $5.2B |
| 2025 | oral GLP-1 programs | Septerna | — | unknown | — | $2.2B |
| 2025 | small molecules targeting non-incretin GPCR | Deep Apple Therapeutics | obesity and cardiometabolic diseases | unknown | — | $812M |
| 2025 | cardiometabolic therapies | Gensaic | cardiometabolic disorders | discovery | — | $354M |
| 2025 | small molecules for non-incretin GPCR target | Deep Apple | obesity and cardiometabolic diseases | discovery | — | $812M |
| 2025 | LX9851 | Lexicon Pharmaceuticals | obesity | preclinical | $75M | $1.0B |
| 2025 | UBT251 | United Laboratories | Obesity, Type 2 Diabetes | phase_1 | $200M | $2.0B |
| 2024 | AI-discovered small molecule MASH drug | Cellarity | MASH | discovery | — | $500M |
| 2024 | heart_failure | Cardior Pharmaceuticals | heart_failure | phase_2 | $1.1B | $1.1B |
| 2024 | thalassemia | Disc Medicine | thalassemia | phase_2 | $100M | $1.2B |
| 2024 | obesity | MBX Biosciences | obesity | phase_1 | $40M | $610M |
| 2024 | hemophiliaB | Catalyst Biosciences | hemophiliaB | phase_3 | $175M | $1.1B |
How this is computed
For each Novo Nordisk deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 18 disclosed deal premiums vs. peer medians. Raw premium 0.666, clamped to [0.7, 1.5].